Maggie L. Shaw

The 2 therapies, a 1-food and a 6-food elimination diet both used for eosinophilic esophagitis (EoE), were compared for outcomes after 6 weeks.

Deepak L. Bhatt, MD, MPH, Icahn School of Medicine at Mount Sinai, has multiple presentations during the upcoming American College of Cardiology Scientific Sessions, including additional phase 2 results from the ENTRIGUE trial for pegozafermin in severe hypertriglyceridemia. 

Stephen M. Schleicher, MD, MBA, chief medical officer at Tennessee Oncology, discusses the present state of value-based oncology care and what the future may bring when the Enhancing Oncology Model kicks off on July 1.

Study results presented at this year’s American Academy of Allergy Asthma & Immunology annual meeting displayed dupilumab efficacy in children aged 6 months to 5 years who had atopic dermatitis (AD).

Outcomes from the loop diuretics were compared in this analysis, with study participants from the TRANSFORM-HF trial matched 1:1, all having been hospitalized for either do novo disease or worsening chronic disease.

David A. Eagle, MD, New York Cancer & Blood Specialists, discusses the present state of treatment for cancer, which often sees patient financial concerns outweighed by the cost of treatment.

In this analysis, evidence was reviewed for the effectiveness of intranasal corticosteroids, biologics, and aspirin therapy after desensitization use among patients who have chronic rhinosinusitis with nasal polyposis (CRSwNP).

Tochi M. Okwuosa, DO, Rush University Medical Center, discusses ways in which cancer treatments can adversely affect heart health outcomes for patients under the care of oncologists.

Investigators compared these outcomes due to limited research in the space, with previous surveys suggesting care disparities.

On this episode of Managed Care Cast, we speak with Simon F. Haeder, PhD, MPA, professor of public health at the Texas A&M University School of Public Health. He and his co-investigators looked at the accuracy of directories of psychiatrists and nonphysician mental health providers for all plans regulated by the California Department of Managed Health Care in 2018 and 2019.

We’ve found through health equity initiatives that the search for the right telehealth modality is never ending, explained Oncology Consultants of Houston’s Susan Sabo-Wagner, MSN, RN, OCN, executive director of clinical strategy.

This review and meta-analysis included 34 studies covering 1762 patients, and investigated the efficacy of 4 varieties of dietary treatment for eosinophilic esophagitis (EoE).

At Carolina Blood and Cancer Care Associates, the No One Left Alone (NOLA) initiative is working to break down cancer health disparities among its patients by addressing the social determinants of health that may be preventing equitable access to care.

This study investigated the impact atopic dermatitis (AD) has on out-of-pocket (OOP) costs for caregivers of pediatric patients with the chronic skin condition.

Implications of these findings include a more clear understanding of the burden imposed by heart failure (HF), which encompasses the cost of care and adverse health outcomes.

This exploration of eczema self-management investigated the potential effectiveness of 2 online behavioral interventions, 1 each for young patients and their parents and/or caregivers.

The authors conducted a subanalysis of data on 100,000-plus children from 3 studies to estimate the global prevalence and severity of eczema; they used linear mixed models to do so.

On this episode of Managed Care Cast, we speak with Tom Stanis, CEO and cofounder of Story Health, and Phillip Wood, Intermountain Ventures program director, on how their partnership came about, how it is going so far, and the future of their collaboration.

Coverage from the 64th Annual American Society of Hematology Meeting and Exposition, December 10-13, 2022, New Orleans, Louisiana.

Tochi M. Okwuosa, DO, cardiologist and director of cardio-oncology at Rush University Medical, discusses the multidisciplinary process that underlies caring for patients with cancer who may develop heart damage.

With atopic dermatitis (AD) prevalence increasing around the world, primarily in developing countries, investigators evaluated the potential for pollution to have an impact on development of the chronic skin condition among an adult population.

Known to be a contributing factor to polyp development at high levels, periostin’s potential as a biomarker for eosinophilic chronic rhinosinusitis (ECRS) severity was investigated in a new study in which outcomes were compared between patients who had ECRS and those with non-ECRS.

Investigators found a higher overall health care burden among a large cohort of patients despite their recovery from sepsis, with potential long-term implications and higher risk of cardiovascular disease.

A team of experts from the United States and Canada performed this systematic review, considering for the first time patient values and preferences for their atopic dermatitis (AD) care.

To mark the publication of The American Journal of Managed Care®’s 12th annual health IT issue, on this episode of Managed Care Cast, we speak with Christopher M. Whaley, PhD, health care economist at the RAND Corporation, who focuses on health economics issues, including the influence of the COVID-19 pandemic on health care delivery.

Outcomes were investigated among 541 patients who had chronic rhinosinusitis; they accounted for 435 primary surgeries and 106 revisionist surgeries.

Using data from the Southern Community Cohort Study, investigators compared outcomes between Black and White participants for heart failure risk.

Following member surveys, expert interviews, and roundtable discussions, the American College of Allergy, Asthma, and Immunology (ACAAI) has released new recommendations for overcoming care disparities among those who have atopic dermatitis (AD) and food allergies.

Pharmaceutical companies would have to spend a lot of money on pediatric anticoagulation studies for diseases that are rare among these patients, explained Michael A. Portman, MD, FAHA, of Seattle Children's Hospital.